Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Romond EH; Perez EA; Bryant J; Suman VJ; Geyer CE Jr; Davidson NE; Tan-Chiu E; Martino S; Paik S; Kaufman PA; Swain SM; Pisansky TM; Fehrenbacher L; Kutteh LA; Vogel VG; Visscher DW; Yothers G; Jenkins RB; Brown AM; Dakhil SR; Mamounas EP; Lingle WL; Klein PM; Ingle JN; Wolmark N; The New England Journal Of Medicine, 2005, vol. 353, issue 16, p 1673, ISSN 15334406. ISBN 15334406.
Full Text Resources Located for this Citation